publication date: Oct. 12, 2018

NCI Trials

NCI Trials for October

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

For further information, contact the principal investigator listed.


Phase II – 10136

A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients with CCNE1 Amplification

University of Texas MD Anderson Cancer Center LAO

Fu, Siqing

(713) 792-4318


Phase II – APEC1621J

NCI-COG Pediatric Molecular Analysis for Therapy Choice (MATCH) – Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations

Children’s Oncology Group

Vo, Kieuhoa Tran

(415) 476-3831

Phase II – AREN1721

A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups

Children’s Oncology Group

Geller, James Ian

(513) 636-6312 X 6312


Phase II – CITN-14

A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Cancer Immunotherapy Trials Network

Yu, Evan Ya-Wen

(206) 288-6292


Phase II – NRG-GY016

A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary

NRG Oncology

Gien, Lilian Tran

(416) 480-4378


Phase II – S1706

A Phase II Randomized … Continue reading NCI Trials for October 2018

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.